The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $242,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Methodist Hospital Research Institute in Houston, Texas. The grant supports research to evaluate the translational potential of two novel strategies, salivabactin and an engineered probiotic, to treat or prevent Group B Streptococcus (GBS) infections in preclinical mouse models. GBS is a major human pathogen that causes stillbirths, preterm births, and neonatal mortality worldwide. The research aims to fully assess the efficacy of salivabactin, a previously unknown antibiotic produced by a human probiotic, and a salivabactin-hyperproducing engineered probiotic for controlling GBS infections across various disease manifestations. The project period runs from November 2024 to October 2026.
Generated 2/25/25, 1:56 AM